Terumo Corp. (OTCMKTS:TRUMY – Get Free Report)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $14.24, but opened at $13.7050. Terumo shares last traded at $13.66, with a volume of 33,835 shares traded.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on TRUMY shares. Zacks Research upgraded shares of Terumo to a “hold” rating in a research note on Thursday, April 9th. Nomura upgraded shares of Terumo to a “hold” rating in a research note on Tuesday, February 24th. Two equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, Terumo currently has a consensus rating of “Hold”.
Read Our Latest Analysis on TRUMY
Terumo Price Performance
Terumo (OTCMKTS:TRUMY – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported $0.11 earnings per share for the quarter, meeting the consensus estimate of $0.11. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.84 billion. Terumo had a return on equity of 9.17% and a net margin of 12.09%. As a group, sell-side analysts forecast that Terumo Corp. will post 0.63 earnings per share for the current fiscal year.
Terumo Company Profile
Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.
Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.
Recommended Stories
- Five stocks we like better than Terumo
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
- ERock IPO: A $1.3B Power Play Solution
- The AI Boom Has a Hidden Winner—And It’s Not Nvidia
- SMX: Can Molecular Tracking Technology Become the Next Moonshot?
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
